Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant , regardless of -derived cephalosporinase allele.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672432 | PMC |
| http://dx.doi.org/10.1093/ofid/ofaa469 | DOI Listing |
Publication Analysis
Top Keywords
activity ceftolozane/tazobactam
8
vitro hollow-fiber
4
hollow-fiber studies
4
studies assessing
4
assessing antibacterial
4
antibacterial activity
4
ceftolozane/tazobactam multidrug-resistant
4
multidrug-resistant hollow-fiber
4
hollow-fiber infection
4
infection model
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!